# US 2012/0251493 A1 · Novel macrocyclic inhibitors of hepatitis c virus replication

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251493 A1
- Document ID: US20120251493A1
- Status: Published application
- Kind: A1
- Application number: 13/497,740
- Filed: 2010-09-24
- Published: 2012-10-04
- Earliest claimed: 2009-09-28
- Inventors: Scott D. Seiwert; John B. Nicholas; Brad Buckman; Vladimir Serebryany
- Web page: https://patentgrep.com/patent/US20120251493A1

## CPC

- A61K 38/05: Dipeptides
- A61K 38/21: Interferons {[IFN]}
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 31/14: for RNA viruses
- C07K 5/0804: {and aliphatic}
- C07K 5/0827: {containing heteroatoms different from O, S, or N}
- A61K 38/07: Tetrapeptides
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The embodiments provide compounds of the general Formula I, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

## Claims

### Claim 1

A compound having the structure of Formula (I):
or a pharmaceutically acceptable salt or prodrug thereof,
wherein W1, W2, W2 and W4 are independently -D or —H, provided that at least one of W1, W2, W2 and W4 is -D;
R1 is selected from the group consisting of —C(O)OR1e, optionally substituted heteroaryl, and aryl optionally substituted with one or more substituents each independently selected from the group consisting of halo, amino, C1-6 alkyl optionally substituted with up to 5 fluoro, C1-6 alkoxy optionally substituted with up to 5 fluoro, C2-6 alkenyl, C2-6 alkynyl, —C(O)NR1aR1b, —NHC(O)NR1aR1b, —C(O)OR1c, and heteroaryl;
R1e is selected from the group consisting of t-butyl, cycloalkyl, and heterocyclyl;
R1a and R1b are taken together with the nitrogen to which they are attached to form piperazinyl or morpholinyl, each optionally substituted with one or more substituents independently selected from optionally substituted C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, —C(O)OR1c, —C(O)R1d, optionally substituted aryl, and optionally substituted heteroaryl;
R1c and R1d are each separately selected from the group consisting of —H, C1-4 alkoxy, C1-6 alkyl, C3-7 cycloalkyl, aryl, arylalkyl and heteroaryl;
R3 is —OH, —NHS(O)2R3a, —NHS(O)2OR3a or —NHS(O)2NR3bR3c; where R1a is selected from the group consisting of C1-6 alkyl, —(CH2)qC3-7cycloalkyl, —(CH2)qC6 or 10aryl, and a heteroaryl, each optionally substituted with one or more substituents each independently selected from the group consisting of halo, cyano, nitro, hydroxy, —COOH, —(CH2)tC3-7cycloalkyl, C2-6 alkenyl, hydroxy-C1-6alkyl, C1-6 alkyl optionally substituted with up to 5 fluoro, and C1-6 alkoxy optionally substituted with up to 5 fluoro;
wherein R3b and R1c are each separately a hydrogen atom, or separately selected from the group consisting of C1-6 alkyl, —(CH2)qC3-7cycloalkyl, and C6 or 10 aryl, each optionally substituted with one or more substituents each independently selected from the group consisting of halo, cyano, nitro, hydroxy, —(CH2)tC3-7cycloalkyl, C2-6 alkenyl, hydroxy-C1-6alkyl, phenyl, C1-6 alkyl substituted with up to 5 fluoro, and C1-6 alkoxy substituted with up to 5 fluoro; or R3b and R1c are taken together with the nitrogen to which they are attached to form a three- to six-membered heterocyclic ring, bonded to the parent structure through a nitrogen, and the heterocylic ring is optionally substituted with one or more substituents each independently selected from the group consisting of halo, cyano, nitro, C1-6 alkyl, C1-6 alkoxy, and phenyl;
each t is independently 0, 1 or 2;
each q is independently 0, 1 or 2; and
any bond represented by a dashed and solid line represents a bond selected from the group consisting of a single bond and a double bond.

### Claim 2 (depends on 1)

The compound of claim 1 selected from the group consisting of:

### Claim 3 (depends on 1)

A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of claim 1.

### Claim 4 (depends on 1)

A method of inhibiting NS3/NS4 protease activity comprising contacting a NS3/NS4 protease with a compound of claim 1.

### Claim 5 (depends on 4)

The method of claim 4 in which the contacting is conducted in vivo.

### Claim 6 (depends on 5)

The method of claim 5, further comprising identifying a subject suffering from a hepatitis C infection and administering the compound to the subject in an amount effective to treat the infection.

### Claim 7 (depends on 6)

The method of claim 6, wherein the method further comprises administering to the individual an effective amount of a nucleoside analog.

### Claim 8 (depends on 7)

The method of claim 7, wherein the nucleoside analog is selected from ribavirin, levovirin, viramidine, an L-nucleoside, and isatoribine.

### Claim 9 (depends on 6)

The method of claim 6, wherein the method further comprises administering to the individual an effective amount of a human immunodeficiency virus 1 protease inhibitor.

### Claim 10 (depends on 9)

The method of claim 9, wherein the protease inhibitor is ritonavir.

### Claim 11 (depends on 6)

The method of claim 6, wherein the method further comprises administering to the individual an effective amount of an NS5B RNA-dependent RNA polymerase inhibitor.

### Claim 12 (depends on 6)

The method of claim 6, wherein the method further comprises administering to the individual an effective amount of interferon-gamma (IFN-γ).

### Claim 13 (depends on 12)

The method of claim 12, wherein the IFN-γ is administered subcutaneously in an amount of from about 10 μg to about 300 μg.

### Claim 14 (depends on 6)

The method of claim 6, wherein the method further comprises administering to the individual an effective amount of interferon-alpha (IFN-α).

### Claim 15 (depends on 14)

The method of claim 14, wherein the IFN-α is monoPEG-ylated consensus IFN-α administered at a dosing interval of every 8 days to every 14 days.

### Claim 16 (depends on 14)

The method of claim 14, wherein the IFN-α is monoPEG-ylated consensus IFN-α administered at a dosing interval of once every 7 days.

### Claim 17 (depends on 14)

The method of claim 14, wherein the IFN-α is INFERGEN consensus IFN-α.

### Claim 18 (depends on 6)

The method of claim 6 further comprising administering an effective amount of an agent selected from 3′-azidothymidine, 2′,3′-dideoxyinosine, 2′,3′-dideoxycytidine, 2′,3′-didehydro-2′,3′-dideoxythymidine (stavudine), combivir, abacavir, adefovir dipoxil, cidofovir, and an inosine monophosphate dehydrogenase inhibitor.

### Claim 19 (depends on 6)

The method of claim 6, wherein a sustained viral response is achieved.

### Claim 20 (depends on 6)

The method of claim 6, in which the contacting is conducted ex vivo.

### Claim 21 (depends on 1)

A method of treating liver fibrosis in an individual, the method comprising administering to the individual an effective amount of a compound of claim 1.

### Claim 22 (depends on 21)

The method of claim 21, wherein the method further comprises administering to the individual an effective amount of a nucleoside analog.

### Claim 23 (depends on 22)

The method of claim 22, wherein the nucleoside analog is selected from ribavirin, levovirin, viramidine, an L-nucleoside, and isatoribine.

### Claim 24 (depends on 21)

The method of claim 21, wherein the method further comprises administering to the individual an effective amount of a human immunodeficiency virus 1 protease inhibitor.

### Claim 25 (depends on 24)

The method of claim 24, wherein the protease inhibitor is ritonavir.

### Claim 26 (depends on 21)

The method of claim 21, wherein the method further comprises administering to the individual an effective amount of an NS5B RNA-dependent RNA polymerase inhibitor.

### Claim 27 (depends on 21)

The method of claim 21, wherein the method further comprises administering to the individual an effective amount of interferon-gamma (IFN-γ).

### Claim 28 (depends on 27)

The method of claim 27, wherein the IFN-γ is administered subcutaneously in an amount of from about 10 μg to about 300 μg.

### Claim 29 (depends on 21)

The method of claim 21, wherein the method further comprises administering to the individual an effective amount of interferon-alpha (IFN-α).

### Claim 30 (depends on 29)

The method of claim 29, wherein the IFN-α is monoPEG-ylated consensus IFN-α administered at a dosing interval of every 8 days to every 14 days.

### Claim 31 (depends on 29)

The method of claim 29, wherein the IFN-α is monoPEG-ylated consensus IFN-α administered at a dosing interval of once every 7 days.

### Claim 32 (depends on 29)

The method of claim 29, wherein the IFN-α is INFERGEN consensus IFN-α.

### Claim 33 (depends on 21)

The method of claim 21, further comprising administering an effective amount of an agent selected from 3′-azidothymidine, 2′,3′-dideoxyinosine, 2′,3′-dideoxycytidine, 2′,3′-didehydro-2′,3′-dideoxythymidine (stavudine), combivir, abacavir, adefovir dipoxil, cidofovir, and an inosine monophosphate dehydrogenase inhibitor.

### Claim 34 (depends on 1)

A method of increasing liver function in an individual having a hepatitis C virus infection, the method comprising administering to the individual an effective amount of a compound of claim 1.

### Claim 35 (depends on 34)

The method of claim 34, wherein the method further comprises administering to the individual an effective amount of a nucleoside analog.

### Claim 36 (depends on 35)

The method of claim 35, wherein the nucleoside analog is selected from ribavirin, levovirin, viramidine, an L-nucleoside, and isatoribine.

### Claim 37 (depends on 34)

The method of claim 34, wherein the method further comprises administering to the individual an effective amount of a human immunodeficiency virus 1 protease inhibitor.

### Claim 38 (depends on 37)

The method of claim 37, wherein the protease inhibitor is ritonavir.

### Claim 39 (depends on 34)

The method of claim 34, wherein the method further comprises administering to the individual an effective amount of an NS5B RNA-dependent RNA polymerase inhibitor.

### Claim 40 (depends on 39)

The method of claim 39, wherein the method further comprises administering to the individual an effective amount of interferon-gamma (IFN-γ).

### Claim 41 (depends on 40)

The method of claim 40, wherein the IFN-γ is administered subcutaneously in an amount of from about 10 μg to about 300 μg.

### Claim 42 (depends on 34)

The method of claim 34, wherein the method further comprises administering to the individual an effective amount of interferon-alpha (IFN-α).

### Claim 43 (depends on 42)

The method of claim 42, wherein the IFN-α is monoPEG-ylated consensus IFN-α administered at a dosing interval of every 8 days to every 14 days.

### Claim 44 (depends on 42)

The method of claim 42, wherein the IFN-α is monoPEG-ylated consensus IFN-α administered at a dosing interval of once every 7 days.

### Claim 45 (depends on 42)

The method of claim 42, wherein the IFN-α is INFERGEN consensus IFN-α.

### Claim 46 (depends on 34)

The method of claim 34, further comprising administering an effective amount of an agent selected from 3′-azidothymidine, 2′,3′-dideoxyinosine, 2′,3′-dideoxycytidine, 2′,3′-didehydro-2′,3′-dideoxythymidine (stavudine), combivir, abacavir, adefovir dipoxil, cidofovir, and an inosine monophosphate dehydrogenase inhibitor.
